Detalhe da pesquisa
1.
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Cancer
; 127(6): 905-913, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231879
2.
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 25(9): 1720-1729, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31039409
3.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Cancer
; 125(14): 2474-2487, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30920645
4.
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
N Engl J Med
; 375(8): 740-53, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27292104
5.
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Am J Hematol
; 94(4): 408-416, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30623490
6.
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Cancer
; 124(8): 1722-1732, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381191
7.
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Br J Haematol
; 174(4): 571-81, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27101934
8.
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Br J Haematol
; 191(3): e77-e81, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32805058
9.
Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
N Engl J Med
; 375(21): 2100-2101, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959720
10.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Blood Adv
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607410
11.
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Br J Haematol
; 182(4): 583-586, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677896
12.
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
Cancer Chemother Pharmacol
; 91(5): 441-446, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892676
13.
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Cancer Sci
; 103(5): 933-8, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22335424
14.
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Clin Lymphoma Myeloma Leuk
; 22(9): e836-e843, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643855
15.
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Clin Transl Sci
; 14(1): 184-193, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812370
16.
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
Bone Marrow Transplant
; 56(6): 1474-1477, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33564120
17.
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Clin Cancer Res
; 27(10): 2742-2754, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602684
18.
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.
J Exp Med
; 197(11): 1585-98, 2003 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12782720
19.
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
Blood Cancer J
; 10(8): 81, 2020 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32769965
20.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Leuk Res
; 88: 106283, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31790983